Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease (Q36577266)

15 August 2017

1 reference

title

Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease (English)

1 reference

15 August 2017

0 references

0 references

Mary N Haan

1

1 reference

PubMed ID

16932542

15 August 2017

language of work or name

1 reference

1 March 2006

1 reference

Nature Clinical Practice Neurology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

3

1 reference

15 August 2017

159-166

1 reference

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Can dementia be prevented? Brain aging in a population-based context

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Diabetes mellitus and the risk of dementia: The Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Hyperinsulinemia and risk of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

The risk of dementia among persons with diabetes mellitus: a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Demonstrating the case that AD is a vascular disease: epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Increased risk of type 2 diabetes in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Small vessel disease and Alzheimer's dementia: pathological considerations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Insulin resistance in cognitive impairment: the InCHIANTI study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Insulin and neurodegenerative disease: shared and specific mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Obesity, regional body fat distribution, and the metabolic syndrome in older men and women

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

An 18-year follow-up of overweight and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Weight loss precedes dementia in community-dwelling older adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Genetics, lifestyle and the roles of amyloid beta and oxidative stress in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Inflammatory pathways and insulin action

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Plasma homocysteine as a risk factor for dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Homocysteine and brain atrophy on MRI of non-demented elderly

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Vascular risk factors, incidence of MCI, and rates of progression to dementia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0124

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0124

1 reference

15 August 2017

1 reference

PubMed ID

16932542